Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Women of childbearing potential must have a negative serum pregnancy test within 24 hours prior to the start of study drug~* Diagnosis of ulcerative colitis confirmed by endoscopic and histologic evidence (if no previous confirmation of diagnosis is available or if diagnosis is not conclusive, at time of baseline endoscopy, histology must be performed and read locally to confirm diagnosis)~Exclusion Criteria:~* Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or hepatitis C~* Subjects with history of cancer, lymphoproliferative disease, class III or IV congestive heart failure, myocardial infarction, unstable angina pectoris, or any history of significant ocular disease such as glaucoma or retinal disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Single Ascending Dose (SAD) - IV Panel (Type: EXPERIMENTAL): Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
- Single Ascending Dose (SAD) - SC Panel (Type: EXPERIMENTAL): Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
- Multiple Ascending Dose (MAD) - IV Panel (Type: EXPERIMENTAL): Multiple IV doses of BMS-986184 or placebo matching BMS-986184
- Proof of Mechanism (POM) - IV Panel (Type: EXPERIMENTAL): Multiple IV doses of BMS-986184 or placebo matching BMS-986184

Based on this trial design, predict the completion outcome and termination type (if applicable).